Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

for income taxes 119.7 127.1

Depreciation (includes accelerated

depreciation) 95.6 95.6

Amortization 80.8 80.8

EBITDA 507.0 527.0

Adjusted for:

Global supply chain initiative 23.4 23.4

Share-based compensation 16.7 16.7

Licensing charges 6.0 6.0

Loss on early extinguishment of debt 1.9 1.9

Adjusted EBITDA $555.0 $575.0

The reconciliation table is based in part on management's estimate of adjusted EBITDA for the year ending December 31, 2008. Watson expects certain known GAAP charges for 2008, as presented in the schedule above. Other GAAP charges that may be excluded from estimated EBITDA are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges, such as potential asset impairment charges, are dependent upon future events and valuations that have not yet been performed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... LAWRENCEVILLE, N.J. , May 28, 2015 ... announced that it has received commitments from two institutional ... million of the Company,s common stock in an at-the-market ... warrants to purchase common stock. The Company ... pursuant to which the Company agreed to sell an ...
(Date:5/28/2015)... 2015 BioNorth Texas (BioNorthTX), an ... the life sciences industry in northern region of ... at The Foundry in Dallas on April 27, ... together a broad spectrum of biotech professionals from ... early successes in partnering with key life sciences ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
(Date:5/28/2015)... Fertility Centers of New England is proud to announce ... a new and expanded role as Medical Director. In ... and quality assurance for the practice. , “We are ... experienced reproductive endocrinologists,” said Fertility Centers of New England ... and compassionate, individualized care have helped set FCNE apart ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... Inc.,(NASDAQ: VSGN ; TSX:VAS), today announced that it ... its cash burn rate and focus its,efforts on ... most,likely to provide long-term shareholder value. This plan ... series of drugs while the,Company seeks alternatives to ...
... April 14 Metabolex, Inc., a,biopharmaceutical company ... new medicines for the treatment of metabolic ... joined the company as chief,financial officer. Mr. ... to Metabolex, including expertise in business,development, treasury ...
... form basis of blood-based ColonSentry(TM) test -, ... GEN),a company focused on developing blood-based biomarker tests ... management, today reported,positive performance results from a large ... assessment of a patient,s current risk for,colorectal cancer. ...
Cached Biology Technology:Vasogen Announces Implementation of Strategic Restructuring Plan 2Vasogen Announces Implementation of Strategic Restructuring Plan 3Vasogen Announces Implementation of Strategic Restructuring Plan 4Vasogen Announces Implementation of Strategic Restructuring Plan 5Metabolex Appoints Donald Hill as Chief Financial Officer 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
(Date:5/22/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... its promotional pricing and making the Wocket generally available for ... , Head of Marketing said, "We,ve extended the opportunity to ... of May. To get your wocket at this special price, ... store on June 1, you,ll receive a unique code that ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... to adapt to moderate climate warming, improving their chance of ... large reductions in carbon dioxide emissions, according to a study ... its academic partners. Results further suggest corals have already adapted ... modeling work suggested that coral reefs would be gone by ...
... Recent years have seen significant outbreaks of listeriosis on ... usually be treated successfully, it is occasionally fatal, most ... when treatment is effective, the symptoms are anything but ... diarrhoea and other gastrointestinal symptoms. The old adage is ...
... is a lead partner in a new 6 million ... treat Cystic Fibrosis. Affecting more than 10,000 people ... the most common life-threatening inherited diseases. Symptoms include repeated ... The new global programme, known as CF Matters, aims ...
Cached Biology News:New study suggests coral reefs may be able to adapt to moderate climate change 2New study suggests coral reefs may be able to adapt to moderate climate change 3Passing the Gac 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
... GenBank Accession Number : ... (C-QSQENQDTRPKVKAKK), corresponding to amino acids ... Formulation: antiserum in 0.05% sodium ... Assurance: routinely evaluated by immunoblot ...
Request Info...
...
Biology Products: